Higher expression of SATB2 in hepatocellular carcinoma of African Americans determines more aggressive phenotypes than those of Caucasian Americans.
AC133 Antigen
/ metabolism
Black or African American
CD24 Antigen
/ metabolism
Carcinoma, Hepatocellular
/ ethnology
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cell Survival
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Gene Expression Regulation, Neoplastic
Gene Knockout Techniques
Humans
Hyaluronan Receptors
/ metabolism
Kruppel-Like Factor 4
Kruppel-Like Transcription Factors
/ metabolism
Liver Neoplasms
/ ethnology
Matrix Attachment Region Binding Proteins
/ genetics
MicroRNAs
/ genetics
Neoplastic Stem Cells
/ metabolism
Octamer Transcription Factor-3
/ metabolism
Proto-Oncogene Proteins c-myc
/ metabolism
SOXB1 Transcription Factors
/ metabolism
Spheroids, Cellular
/ metabolism
Transcription Factors
/ genetics
Tumor Cells, Cultured
White People
KLF4
OCT4
SATB2
SOX2
c-Myc
cancer stem cells
hepatocellular carcinoma
miR-34a
pluripotency
self-renewal
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
16
07
2019
accepted:
16
08
2019
pubmed:
12
10
2019
medline:
21
10
2020
entrez:
12
10
2019
Statut:
ppublish
Résumé
In the United States, Hepatocellular Carcinoma (HCC) incidence has tripled over the past two decades. The disease has disproportionately affected minority and disadvantaged populations. The purpose of this study was to examine the expression of SATB2 gene in HCC cells derived from African Americans (AA) and Caucasian Americans (CA) and assess its oncogenic potential by measuring cell viability, spheroid formation, epithelial-mesenchymal transition (EMT), stem cell markers and pluripotency maintaining factors in cancer stem cells (CSCs). We compared the expression of SATB2 in human primary hepatocytes, HCC cells derived from AA and CA, and HCC CSCs. Hepatocellular carcinoma cells derived from AA expressed the higher level of SATB2 than those from CA. By comparison, normal human hepatocytes did not express SATB2. Higher expression of SATB2 in HCC cells from AA was associated with greater growth rate, cell viability, colony formation and EMT characteristics than those from CA. Knockout of SATB2 in CSCs by Crispr/Cas9 technique significantly inhibited the expression of SATB2 gene, stem cell markers (CD24, CD44 and CD133), pluripotency maintaining factors (c-Myc, KLF4, SOX2 and OCT4), and EMT compared with non-targeting control group. The expression of SATB2 was negatively correlated with miR34a. SATB2 rescued the miR-34a-mediated inhibition of CSC's viability. These data suggest that SATB2 is an oncogenic factor, and its higher expression may explain the disparity in HCC outcomes among AA.
Identifiants
pubmed: 31602781
doi: 10.1111/jcmm.14652
pmc: PMC6850930
doi:
Substances chimiques
AC133 Antigen
0
CD24 Antigen
0
CD24 protein, human
0
Hyaluronan Receptors
0
KLF4 protein, human
0
Kruppel-Like Factor 4
0
Kruppel-Like Transcription Factors
0
MIRN34 microRNA, human
0
MYC protein, human
0
Matrix Attachment Region Binding Proteins
0
MicroRNAs
0
Octamer Transcription Factor-3
0
POU5F1 protein, human
0
PROM1 protein, human
0
Proto-Oncogene Proteins c-myc
0
SATB2 protein, human
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7999-8009Informations de copyright
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Références
Cell Cycle. 2010 Nov 1;9(21):4387-98
pubmed: 20980827
Sci Rep. 2016 Sep 14;6:32743
pubmed: 27624879
PLoS Biol. 2010 Jan 26;8(1):e1000296
pubmed: 20126258
Neuron. 2008 Feb 7;57(3):378-92
pubmed: 18255031
World J Hepatol. 2018 Nov 27;10(11):849-855
pubmed: 30533185
Cell. 2006 Jun 2;125(5):971-86
pubmed: 16751105
J Orthop Res. 2012 Jul;30(7):1058-66
pubmed: 22570222
Neurochem Res. 2006 Feb;31(2):237-46
pubmed: 16604441
Clin Mol Hepatol. 2019 Mar;25(1):12-20
pubmed: 30300991
Sci Rep. 2017 Sep 8;7(1):10939
pubmed: 28887549
Cancer. 2016 Aug 15;122(16):2512-23
pubmed: 27195481
Stem Cells Dev. 2013 Aug 15;22(16):2278-86
pubmed: 23517179
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Eur J Neurosci. 2005 Feb;21(3):658-68
pubmed: 15733084
Gastroenterology. 2009 Mar;136(3):1012-24
pubmed: 19150350
Liver Int. 2009 Aug;29(7):955-65
pubmed: 19490415
Oncol Lett. 2018 Mar;15(3):2985-2991
pubmed: 29435028
J Mol Med (Berl). 2009 Nov;87(11):1097-104
pubmed: 19727638
Clin Gastroenterol Hepatol. 2006 Mar;4(3):355-60
pubmed: 16527700
Hepatology. 2008 Mar;47(3):1058-66
pubmed: 18302296
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Neuro Oncol. 2013 Jun;15(6):691-706
pubmed: 23482671
Am J Gastroenterol. 2014 Apr;109(4):542-53
pubmed: 24513805
Oncotarget. 2016 Sep 6;7(36):57783-57797
pubmed: 27472393
Exp Cell Res. 2013 Jan 15;319(2):126-32
pubmed: 22999864
Springerplus. 2013 Jul 02;2(1):294
pubmed: 23888267
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
J Hepatol. 2010 Feb;52(2):280-1
pubmed: 20006402
Biomed Res Int. 2018 Dec 6;2018:2863902
pubmed: 30627547
Nature. 2004 Oct 28;431(7012):1112-7
pubmed: 15475948
Front Oncol. 2018 Sep 11;8:375
pubmed: 30254987
Int J Cancer. 2009 Nov 15;125(10):2264-9
pubmed: 19585572
Nat Genet. 2006 Nov;38(11):1278-88
pubmed: 17057718
Eur J Neurosci. 2008 Feb;27(4):865-73
pubmed: 18333962
Semin Cancer Biol. 2010 Apr;20(2):77-84
pubmed: 20371287
Hepatology. 2015 Jan;61(1):191-9
pubmed: 25142309
Biomaterials. 2013 Sep;34(28):6717-28
pubmed: 23768901
J Clin Invest. 2003 Dec;112(12):1776-84
pubmed: 14679171
Genes Dev. 2003 Dec 15;17(24):3048-61
pubmed: 14701874
Hum Cell. 2006 Feb;19(1):24-9
pubmed: 16643604
Clin Gastroenterol Hepatol. 2019 Feb;17(3):551-559.e1
pubmed: 29859983
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Arch Surg. 2010 Dec;145(12):1158-63
pubmed: 21173289
Cancer Res. 2008 Mar 1;68(5):1451-61
pubmed: 18316609
Stem Cell Res. 2017 Mar;19:139-147
pubmed: 28167342
Neuron. 2008 Feb 7;57(3):364-77
pubmed: 18255030
J Gastroenterol Hepatol. 2011 Aug;26(8):1229-37
pubmed: 21557770
Int J Mol Sci. 2013 Aug 12;14(8):16600-16
pubmed: 23941782
Hepatology. 2014 Nov;60(5):1767-75
pubmed: 24839253
Gene. 2016 Dec 5;594(1):47-58
pubmed: 27593563
Gastroenterology Res. 2018 Dec;11(6):430-435
pubmed: 30627268
Nanomedicine. 2015 Nov;11(8):2061-70
pubmed: 26199979
Oncotarget. 2015 Apr 20;6(11):9457-66
pubmed: 25888635
J Cell Mol Med. 2018 May 15;:
pubmed: 29761897
J Cell Mol Med. 2019 Dec;23(12):7999-8009
pubmed: 31602781